At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 10 enrolled
Drug / intervention
tafamidisdrug
Likely dose
tafamidis 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect On Transthyretin Stabilization, Safety, Tolerablity, Efficacy And Pharmacokinetics Of Orally Administered Tafamidis In Transthyretin Amyloid Polyneuropathy Patients With V30m Or Non-v30m Transthyretin: A Phase Iii, Open-label Study
In Brief
A Phase 3 clinical trial evaluating tafamidis for Transthyretin Familial Amyloid Polyneuropathy. Completed, enrolled 10 participants across 2 sites.
Detailed Summary
Tafamidis has been developed as an oral specific stabilizer of transthyretin tetramer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 2011
Enrollment StartNov 2011
Primary CompletionFeb 2014
TodayJul 2026
First PostedSep 16, 2011
Enrollment StartNov 1, 2011
Primary CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 14.8 years ago
Interventions
tafamidisdrug
tafamidis meglumine 20 mg QD